Sudden Cardiac Death

Pipeline Programs

Companies

Clinical Trials

Approved Products

Pipeline by Development Stage

Preclinical

Phase 1

Phase 1/2

Phase 2

Phase 2/3

Phase 3

On Market

Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

11 companies ranked by most advanced pipeline stage

Pre

P1/2

P2/3

Mkt

AbbottABBOTT PARK, IL

4 programs

Cardiac Resynchronization Therapy - DefibrillatorPhase 41 trial

Implantable Cardioverter DefibrillatorPhase 41 trial

ICD/ CRT-DN/A1 trial

Magnet or Off-OnN/A

Active Trials

NCT00874445Completed77Est. Sep 2010

NCT00626093Completed77Est. Apr 2010

NCT00311181Completed217Est. Apr 2008

LivaNovaUK - London

2 programs

Ovatio VR 6250 or DR6550Phase 41 trial

Implantable Cardioverter Defibrillators - Improving Risk StratificationN/A

Active Trials

NCT00560768Completed198Est. Oct 2012

Angeles TherapeuticsCA - Los Angeles

2 programs

Cardiac Sympathetic DenervationPhase 31 trial

EC with nicotineN/A1 trial

Active Trials

NCT03916341Completed110Est. Apr 2023

NCT01013714Unknown40Est. Aug 2024

Oregon TherapeuticsFrance - Paris

1 program

Cardiac Sympathetic DenervationPhase 3

ZollCA - San Jose

5 programs

Wearable Cardioverter DefibrillatorN/A1 trial

cardiac rehabilitationN/A1 trial

wearable defibrillatorN/A1 trial

Active Trials

NCT03016754Completed602Est. Jun 2022

NCT03319160Completed1,164Est. Mar 2019

NCT02481206Terminated66Est. Dec 2017

+2 more trials

Boston ScientificCA - Valencia

3 programs

AV Therapy Assessment-B301 investigational deviceN/A1 trial

Arm 1N/A1 trial

Magnet or Off-OnN/A

Active Trials

NCT01074034Completed211Est. Jun 2011

NCT02923726Completed2,692Est. Jul 2023

Young BioPharmaMA - Lowell

1 program

Cardiovascular magnetic resonance scan - 3T scannerN/A1 trial

Active Trials

NCT05799833Unknown240Est. Nov 2025

Innovation PharmaceuticalsMA - Wakefield

1 program

Implantable Cardioverter Defibrillators - Improving Risk StratificationN/A1 trial

Active Trials

NCT01944514Completed92

MedtronicNJ - Phillipsburg

1 program

Magnet or Off-OnN/A1 trial

Active Trials

NCT01599065Completed80Est. Oct 2013

Laurent PharmaceuticalsQC - Montréal

1 program

S-ICDN/A1 trial

Active Trials

NCT05302115Unknown5,000Est. Dec 2024

Martin PharmaceuticalsNY - New York

1 program

S-ICDN/A

Trial Timeline

Clinical trial activity over time

2021

2022

2023

2024

2025

2026

AbbottCardiac Resynchronization Therapy - Defibrillator

LivaNovaOvatio VR 6250 or DR6550

AbbottImplantable Cardioverter Defibrillator

Angeles TherapeuticsCardiac Sympathetic Denervation

Young BioPharmaCardiovascular magnetic resonance scan - 3T scanner

Zollcardiac rehabilitation

Angeles TherapeuticsEC with nicotine

ZollWearable Cardioverter Defibrillator

Boston ScientificArm 1

ZollWearable Cardioverter Defibrillator

Laurent PharmaceuticalsS-ICD

MedtronicMagnet or Off-On

Zollwearable defibrillator

Innovation PharmaceuticalsImplantable Cardioverter Defibrillators - Improving Risk Stratification

Showing 15 of 17 trials with date data

Clinical Trials (17)

Total enrollment: 10,990 patients across 17 trials

NCT00626093 AbbottCardiac Resynchronization Therapy - Defibrillator

'Effect of CRT on Defibrillation Threshold Estimates' Study

Start: Jan 2008Est. completion: Apr 201077 patients

Phase 4Completed

NCT00560768 LivaNovaOvatio VR 6250 or DR6550

Predictive Risk Stratification Through T Variability in ICD Patients Without Pacing Indications

Start: Dec 2007Est. completion: Oct 2012198 patients

Phase 4Completed

NCT00311181 AbbottImplantable Cardioverter Defibrillator

POWER (Pulse Width Optimized Waveform Evaluation Trial)

Start: Aug 2006Est. completion: Apr 2008217 patients

Phase 4Completed

NCT01013714 Angeles TherapeuticsCardiac Sympathetic Denervation

Cardiac Sympathetic Denervation for Prevention of Ventricular Tachyarrhythmias

Start: Jul 2021Est. completion: Aug 202440 patients

Phase 3Unknown

NCT05799833 Young BioPharmaCardiovascular magnetic resonance scan - 3T scanner

Low QRS Voltages in Young Healthy Individuals and Athletes

Start: Oct 2023Est. completion: Nov 2025240 patients

N/AUnknown

NCT04675957 Zollcardiac rehabilitation

Cardiac Rehab Retrospective Review (CR3)

Start: Feb 2021Est. completion: Apr 202255 patients

N/ACompleted

NCT03916341 Angeles TherapeuticsEC with nicotine

Smoking and Ventricular Repolarization

Start: Oct 2019Est. completion: Apr 2023110 patients

N/ACompleted

NCT03016754 ZollWearable Cardioverter Defibrillator

Heart Failure Optimization Study

Start: Mar 2017Est. completion: Jun 2022602 patients

N/ACompleted

NCT03319160 ZollWearable Cardioverter Defibrillator

LifeVest Safety and Efficacy in Real Life Settings in France

Start: Feb 2017Est. completion: Mar 20191,164 patients

N/ACompleted

NCT02923726 Boston ScientificArm 1

Assessment of Primary Prevention Patients Receiving An ICD - Systematic Evaluation of ATP

Start: Sep 2016Est. completion: Jul 20232,692 patients

N/ACompleted

NCT02481206 ZollWearable Cardioverter Defibrillator

Wearable Cardioverter Defibrillator in Hemodialysis Patients (WED-HED) Study

Start: Jun 2015Est. completion: Dec 201766 patients

N/ATerminated

NCT05302115 Laurent PharmaceuticalsS-ICD

S-ICD French Cohort Study (HONEST)

Start: Oct 2012Est. completion: Dec 20245,000 patients

N/AUnknown

NCT01599065 MedtronicMagnet or Off-On

Comparison of a MAGNET Protocol Versus "off-on" Protocol for Patients With Implantable Cardioverter Defibrillators

Start: Dec 2011Est. completion: Oct 201380 patients

N/ACompleted

NCT01448005 Zollwearable defibrillator

LifeVest Post-CABG Registry

Start: Feb 2011Est. completion: Oct 201469 patients

N/ATerminated

NCT01944514 Innovation PharmaceuticalsImplantable Cardioverter Defibrillators - Improving Risk Stratification

Implantable Cardioverter Defibrillators - Improving Risk Stratification

Start: Jan 201092 patients

N/ACompleted

NCT00874445 AbbottICD/ CRT-D

Comparison of 50% Tilt and Tuned Waveforms in Single-Coil Active Can Configuration

Start: Mar 2009Est. completion: Sep 201077 patients

N/ACompleted

NCT01074034 Boston ScientificAV Therapy Assessment-B301 investigational device

REASSURE AV Registry

Start: Apr 2006Est. completion: Jun 2011211 patients

N/ACompleted

Phase Legend

Preclinical— Lab & animal studies

Phase 1— Safety & dosing

Phase 2— Efficacy testing

Phase 3— Large-scale trials

On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs, potential near-term approvals

12 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.